ABIVAX Société Anonyme (NASDAQ:ABVX) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of ABIVAX Société Anonyme (NASDAQ:ABVX) have received an average rating of “Moderate Buy” from the seven brokerages that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $36.50.

Separately, Laidlaw started coverage on ABIVAX Société Anonyme in a report on Monday, July 29th. They issued a “buy” rating and a $48.00 price target on the stock.

Institutional Investors Weigh In On ABIVAX Société Anonyme

Large investors have recently modified their holdings of the business. BNP Paribas Financial Markets acquired a new stake in shares of ABIVAX Société Anonyme during the 1st quarter worth approximately $81,000. Capstone Investment Advisors LLC increased its holdings in ABIVAX Société Anonyme by 9.0% in the 1st quarter. Capstone Investment Advisors LLC now owns 62,966 shares of the company’s stock valued at $900,000 after purchasing an additional 5,199 shares during the last quarter. Kennedy Capital Management LLC raised its position in ABIVAX Société Anonyme by 35.3% in the first quarter. Kennedy Capital Management LLC now owns 120,168 shares of the company’s stock valued at $1,718,000 after purchasing an additional 31,331 shares during the period. Finally, Janus Henderson Group PLC lifted its stake in ABIVAX Société Anonyme by 18.2% during the first quarter. Janus Henderson Group PLC now owns 851,839 shares of the company’s stock worth $12,113,000 after purchasing an additional 131,414 shares in the last quarter. Hedge funds and other institutional investors own 47.91% of the company’s stock.

ABIVAX Société Anonyme Stock Up 0.5 %

Shares of ABVX opened at $10.50 on Thursday. The company has a 50 day moving average price of $11.14 and a 200-day moving average price of $12.76. ABIVAX Société Anonyme has a fifty-two week low of $7.99 and a fifty-two week high of $17.02.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.